Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2/drug therapy; Humans; Hypoglycemic Agents/therapeutic use; Obesity/complications; Piperidines/therapeutic use; Pyrazoles/therapeutic use
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Van Gaal, Luc F
Language :
English
Title :
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Publication date :
2007
Journal title :
European Heart Journal
ISSN :
0195-668X
eISSN :
1522-9645
Publisher :
Oxford University Press, United Kingdom
Volume :
28
Issue :
11
Pages :
1401-2; author reply 1402
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
The original article can be found at http://eurheartj.oxfordjournals.org/content/vol28/issue11/index.dtl#LETTERS_TO_THE_EDITOR
Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Society for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.
Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH for American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-2967.
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880.
Scheen AJ, Finer N, Hollander P, Jensen M, Van Gaal LF for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
Iranmanesh A, Rosenstock J, Hollander P, SERENADE-Study-Group. SERENADE: rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naïve patients with type 2 diabetes (abstract). Diabet Med 2006;23(Suppl. 4):230.
